Blue Ridge Research Center, L.L.C.
Blue Ridge Research Center, LLC, founded in 1995, is a private research entity in partnership with the practice of Dr. John Gordon Burch, PLLC. Blue Ridge Research conducts Phase II and Phase III clinical trials and research activities are ongoing in many subspecialty areas including Multiple Sclerosis, Parkinson's disease, and Alzheimer's disease.
Our research coordinators - Leslie, Linda, and Taylor - manage all the details necessary for participation in our research studies. Details of the studies are reviewed on an individual basis with patients and/or family members. The intent of the study is explained, the inclusion and exclusion criteria for participation are reviewed, and the potential side effects of the medication are considered. The details of the informed consent are discussed with the patient and family members.
We are currently enrolling patients in the following studies:
Multiple Sclerosis
Novartis EPOC
A 6-month, Randomized, Active comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from previous Disease Modifying Therapy.
To be eligible to participate, the following criteria must be met:
-
Diagnosis of a relapsing form of Multiple Sclerosis
-
Age 18-65 years
-
Must have received continuous treatment with a single approved and indicated MS disease modifying therapy for a minimum of 6 months prior to the screening visit.
Parkinson’s Disease
Acadia Pharmaceuticals: Parkinson's Disease Related Psychosis
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the treatment of Psychosis on Parkinson's disease.
To be eligible to participate, the following criteria must be met:
|
